Capstone Therapeutics (NASDAQ:CAPS) Posts Earnings Results, Misses Estimates By $41.39 EPS

Capstone Therapeutics (NASDAQ:CAPS) announced its quarterly earnings results on Thursday. The company reported ($38.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.99 by ($41.39), FiscalAI reports. Capstone Therapeutics had a negative net margin of 36.51% and a negative return on equity of 144.43%. The company had revenue of $19.96 million during the quarter, compared to analysts’ expectations of $22.50 million.

Capstone Therapeutics Price Performance

CAPS stock traded down $0.23 during midday trading on Thursday, hitting $1.79. 113,323 shares of the stock were exchanged, compared to its average volume of 89,850. The stock’s 50-day moving average price is $3.88 and its 200-day moving average price is $10.27. The stock has a market cap of $1.65 million, a price-to-earnings ratio of -0.02 and a beta of -1.35. Capstone Therapeutics has a fifty-two week low of $1.74 and a fifty-two week high of $34.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.39 and a current ratio of 0.99.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Capstone Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, November 4th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury. The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.